Normal Plasma Levels of Cardiac Troponin I Measured by the High-Sensitivity Cardiac Troponin I Access Prototype Assay and the Impact on the Diagnosis of Myocardial Ischemia  by Venge, Per et al.
T
t
i
a
F
a
D
B
D
h
a
r
s
2
Journal of the American College of Cardiology Vol. 54, No. 13, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PBiomarkers
Normal Plasma Levels of Cardiac
Troponin I Measured by the High-Sensitivity
Cardiac Troponin I Access Prototype Assay and
the Impact on the Diagnosis of Myocardial Ischemia
Per Venge, MD, PHD,* Nina Johnston, MD, PHD,† Bertil Lindahl, MD, PHD,†‡
Stefan James, MD, PHD†‡
Uppsala, Sweden
Objectives This study sought to evaluate the analytical and clinical performance of the novel hypersensitive cardiac tropo-
nin I (cTnI) prototype assay from Beckman Coulter (Fullerton, California).
Background Studies on patients with acute coronary syndromes and on seemingly healthy subjects have shown that even
very minor elevations of cardiac troponins are associated with an increased risk of death. However, the normal
plasma levels of cardiac troponins are still not known.
Methods cTnI plasma levels were measured in 542 healthy subjects, 319 men (age 59.9  11.8 years) and 213 women
(age 59.8  13.1 years), and in 1,503 randomly selected patients of the GUSTO IV (Global Utilization of Strate-
gies To open Occluded arteries IV) cohort with unstable angina and non–ST-segment elevation myocardial infarc-
tions (MIs).
Results The cTnI levels at 10% coefficient of variation and 20% coefficient of variation imprecision were 0.0033 and
0.0016 g/l, respectively. The cTnI levels were measurable in 95% of the healthy subjects. The median level
of healthy subjects 60 years of age was 0.0032 g/l (range 0.0011 to 0.0079 g/l) with the 99th percentile
being 0.010 g/l. No sex differences were observed. A receiver-operator characteristic curve analysis showed an
optimal discrimination between healthy subjects and patients at 0.0064 g/l with a sensitivity of 84.8% (95%
confidence interval: 82.8% to 86.6%) and specificity of 89.7% (95% confidence interval: 86.8% to 92.2%). Out-
comes as to death and/or MI were significantly different at this level (p  0.01) in the GUSTO IV cohort.
Conclusions The novel high-sensitivity cTnI prototype assay from Beckman Coulter allows for the first time the measurement
of cTnI levels in almost all healthy subjects. Our data indicate that the assay may be a powerful aid in the diag-
nosis and outcome prediction of patients with suspected myocardial ischemia and question any definition of
myocardial infarction. (J Am Coll Cardiol 2009;54:1165–72) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.051h
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phe assay of blood levels of cardiac troponins has become
he recommended procedure for the detection of cardiac
njury in patients with the acute coronary syndrome (ACS)
nd acute myocardial infarction (AMI) (1). Elevated levels,
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009, accepted May 4, 2009.owever, may also be seen in subjects without apparent
igns of cardiovascular disease and are in these cases impor-
ant predictors of future episodes of AMI and/or premature
eath in cardiovascular disease (2,3). As recommended by
he consensus documents, cardiac troponins should be
See page 1173
easurable at the 99th percentile of the upper reference
imit (URL) in healthy subjects with a maximum impreci-
ion of 10% coefficient of variation (CV) (4,5), a require-
ent currently only met by a few available assays. In
revious reports we showed that the 99th percentile is age
ependent, because elderly subjects in many cases had signs
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High-Sensitivity cTnI Access Prototype Assay September 22, 2009:1165–72of elevated levels above those of
younger subjects, suggesting on-
going subclinical processes in a
portion of seemingly healthy
subjects (6). Thus, the proper
definition of the 99th percentile
URL is extremely difficult and
very much dependent on the
study cohort.
Recent developments and im-
provements of cardiac troponin
assays have clearly indicated that
subjects with even very minor
elevations of cardiac troponins
are at increased risk of premature
AMI and/or death (3,7–9). Thus,
the more sensitive the assay is,
the more patients are identified
at risk. The open question there-
fore remains, “How sensitive
hould a cardiac troponin assay be?” This question will only
e answered with a cardiac troponin assay that is able to
easure any elevations with acceptable imprecision, and to
dentify such elevations it is necessary to know what the
ormal levels of cardiac troponins are. In this report we
how the results of such a development, as the recent
rototype cardiac troponin I (cTnI) assay by Beckman
oulter is able to identify troponin I levels in virtually all
ealthy subjects, and this assay allows us to define the
iscrimination between healthy subjects and those with
CS with high accuracy.
atients and Methods
atients. The GUSTO IV (Global Utilization of Strate-
ies To open Occluded arteries IV) trial included 7,800
atients with non–ST-segment elevation ACS from 458
enters in 24 countries during 1999 and 2000 (10,11). The
etailed design and main results of the trial have been
ublished. Eligible patients were 21 years of age with 1 or
ore episodes of angina lasting 5 min, within 24 h of
dmission and either a positive cardiac troponin T (cTnT)
r cTnI test (above the upper limit of normal for the local
ssay) or 0.5 mm of transient or persistent ST-segment
epression. The study was conducted in a double-blind
ashion with patients randomly assigned to 3 treatment
roups: abciximab infusion for 24 or 48 h or corresponding
lacebo infusion. All patients received aspirin, 150 to 325
g orally daily, for long-term treatment as well as either
nfractionated heparin infusion for 48 h (n  6,826) or
ubcutaneous dalteparin every 12th hour for 5 to 7 days
n  974). Coronary angiography was not to be performed
uring or within 12 h after the completion of study agent
nfusion. For this study we selected random serum samples
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
AUC  area under the
curve
CI  confidence interval
cTnI  cardiac troponin I
cTnT  cardiac troponin T
CV  coefficient of
variation
MI  myocardial infarction
ROC  receiver-operator
characteristic
URL  upper reference
limitrom a cohort of 1,503 patients. SThe study on healthy subjects consisted of 537,388 men
median age 62 years, range 28 to 76 years) and 213 women
median age 64 years, range 29 to 76 years), of which 42
ubjects were above the age of 75 years; 384 of the subjects
ere included in the SWISCH (Sweden Women and Men
nd Ischemic Heart Disease) study during 2000 to 2001 and
53 were included in a cohort of healthy employees.
mployees were included if found healthy after a general
hysical examination by a physician, a normal electrocar-
iogram at rest, and a questionnaire-based survey of previ-
us and present disease that did not indicate any health
roblems. The SWISCH study was a case-control study of
isk factors for coronary artery disease in older men and
omen (12). In this study, subjects were randomly recruited
rom the population using the population registry and
atched for age and sex with patients with unstable
oronary artery disease included at 6 hospitals in the FRISC
I (Fragmin and Fast Revascularisation during Instability in
oronary artery disease) trial during 1996 to 1998. Details
f these studies were published previously (13,14). The
RISC II and GUSTO IV trial populations were strikingly
imilar (15,16).
The imprecision profile of the assay was estimated from the
nalysis of duplicate samples of 306 patients admitted to the
mergency department with suspicion of cardiac disease.
he samples were leftover plasma and were analyzed with-
ut knowledge of the identity or diagnosis of the patients.
he procedure was approved by the local ethics committee.
ethods
he cTnI assay was a prototype assay supplied by Beckman
oulter and was run on the Access instrument (Beckman
oulter, Fullerton, California) (17). Levels 10 g/l were
ot further analyzed but assigned the value of 10 g/l. The
ccuTnI assay was run on the Access instrument according
o instructions of the manufacturer.
tatistics. Passing-Bablok regression analysis, Mann-
hitney nonparametric test for group comparisons, chi-
quare test, and receiver-operator characteristic (ROC)
urve analysis were used. The imprecision profile of the
ccess high-sensitivity troponin I assay was estimated
sing the Sadler and Smith method (18). In brief, a
-parameter relationship between variance of the repli-
ate measurements of cTnI with the high-sensitivity
TnI assay and their mean concentrations was estimated
sing unweighted nonlinear least-squares regression.
utliers were identified as samples that were either 3
imes higher or 3 times lower than the interquartile levels
f the whole reference population (19). In Passing-
ablok regression analysis, only results 10 g/l were
ncluded. All calculations were made by the statistical
oftware Medcalc version 9 (Mariakerke, Belgium) and
tatistica for Windows version 8 (Tulsa, Oklahoma).
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he imprecision profile, based on CVs of assaying duplicate
amples of 306 consecutive patients with suspicion of
ardiac disease, showed an estimated 10% CV at 0.0033
g/l and an estimated 20% CV at 0.0016 g/l (Fig. 1).
verall the high-sensitivity cTnI assay was significantly
orrelated to the AccuTnI assay, r2  0.88 (p  0.001)
n  1,343 GUSTO IV samples). A Passing-Bablok regres-
ion analysis showed high-sensitivity cTnI  0.01566 
.6372 AccuTnI with a significant deviation from linearity.
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Figure 1 The Imprecision Profile of the High-Sensitivity cTnI Ac
The inset shows the profile with the x-axis truncated at 0.030 g/l and also the e
coefficients of variation (CVs). The 95% confidence interval of the fitted line is sho
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Figure 2 The Distribution Profile of cTnI in Healthy Subjects
(A) The distribution of cardiac troponin I (cTnI) levels in the seemingly healthy pop
0.030 g/l. (B) All results from the seemingly healthy subjects divided by sex. NoThe cTnI levels in the cohort of seemingly healthy
ubjects are shown in Figure 2 and indicate that 93% of all
amples had levels above the 20% CV cutoff of 0.0016 g/l
nd 50% above the 10% cutoff of 0.0033 g/l. The majority
f results formed a bell-shaped distribution, with 93% of the
esults being 0.010 g/l. With all results from the
eference samples included, the 99th and 97.5th percentiles
ere 0.064 and 0.029 g/l, respectively. After outlier
xclusions the 97.5th and 99th percentiles were found at
.0110 and 0.0144 g/l, respectively. For the cohort 60
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High-Sensitivity cTnI Access Prototype Assay September 22, 2009:1165–72ears of age, the 97.5th and 99th percentiles were 0.012 and
.019 g/l, respectively, and for the cohort60 years of age
ere 0.009 and 0.010 g/l, respectively (Fig. 3). No sex
ifferences were observed in either of these 2 age cohorts
Fig. 3). For the whole cohort, no age difference was found,
hereas among those subjects who had levels 0.010 g/l,
5% were older than 60 years, as compared with 56% in the
ohort with levels 0.010 g/l (p  0.03).
In the analysis of a subset of the GUSTO IV cohort, the
esults showed significantly elevated levels as compared with
he healthy subjects (p 0.001) (Fig. 4). Twenty percent of
he GUSTO IV subjects had levels below 0.010 g/l. An
OC curve analysis including all results from the healthy
ohort showed an area under the curve (AUC) of 0.942
95% confidence interval [CI]: 0.931 to 0.952) with a
ensitivity and specificity in the discrimination between
CS and healthy subjects of 88.4% (95% CI: 86.6% to
9.9%) and 85.0% (95% CI: 81.7% to 87.9%), respectively,
t the optimal cutoff of 0.0064 g/l (Fig. 5). After outlier
xclusion, the AUC increased marginally to 0.948 (not
ignificant). Adopting the 99th percentile cutoffs after
utlier exclusion, that is, 0.01 g/l and 0.019 g/l for those
60 years old and for the whole cohort, respectively, the
pecificities increased substantially to 95.2% and 99.1%,
espectively (Table 1).
The GUSTO IV study protocol does not allow the
istinction between patients with non–ST-segment eleva-
ion myocardial infarction (MI) and unstable angina. As a
urrogate marker for this distinction, we therefore used
TnT with a cutoff of 0.03 g/l, corresponding to the 10%
Outliers = >0.012 µg/L
cT
n
I, 
µg
/L
1
0.1
0.01
0.001
0.0001
WomenMen
High sensitivity cTnI, Access in a healthy reference populatio
below 60 years of age
97.5th percentile :  0.009 µg/L
99th percentile     : 0.010 µg/L
97.5th percentile
99th percentile
A
Figure 3 The 99th and 97.5th Percentile Levels of cTnI in Seem
(A) Data from subjects 60 years of age and divided by sex. (B) Data from subje
were found in either of the 2 cohorts. The percentile levels were defined after excl
60 years of age results 0.028 g/l were defined as outliers. Abbreviations asV level for the third-generation TnT assay on an Elecsys010 (kit insert, Roche Diagnostics, Basel, Switzerland).
e found that 63.1% of the patients had cTnT levels0.03
g/l and 71.2% of the patients had cTnI levels 0.017 g/l
99th percentile for the healthy subjects). Figure 6 shows
he distribution of cTnI levels in these 2 subsets as com-
ared with the healthy reference. The cTnI levels were
-fold and significantly elevated in the subset with cTnT
High sensitivity cTnI, Access in a healthy reference population
above 60 years of age
1
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Outliers = >0.028 µg/L
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99th percentile
97.5th percentile :  0.012 µg/L
99th percentile     : 0.019 µg/L
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y Healthy Subjects
0 years of age and divided by sex. No statistical differences between sexes
of outliers. In subjects 60 years of age results 0.012 g/l and in subjects
re 1.
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Figure 4 cTnI Levels in Healthy Subjects
and Patients With ACS
The comparison of cTnI levels in seemingly healthy subjects and in patients
with the acute coronary syndrome (GUSTO IV [Global Utilization of Strategies To
open Occluded arteries IV]). Results above 10 g/l were assigned 10 g/l.
The difference in cTnI levels between the cohorts was highly significant (p 
0.0001). ACS  acute coronary syndrome; other abbreviations as in Figure 1.n B
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levated cTnT levels were on average more than 500-fold
ncreased. Figure 7 shows the ROC curve analysis of the 2
ubsets and the diagnostic distinction from healthy subjects.
n the subset with nonelevated cTnT, the AUC was 0.848
95% CI: 0.825 to 0.869). The optimal cutoff was 0.0046
g/l, with a corresponding sensitivity and specificity of
9.5% (95% CI: 75.8% to 82.8%) and 76.0% (95% CI:
2.2% to 79.6%), respectively. The positive likelihood ratio
as 3.31 (95% CI: 3.1 to 3.5), and the negative likelihood
as 0.27 (95% CI: 0.2 to 0.3). In the subset with elevated
TnT, the AUC was 0.996 (95% CI: 0.991 to 0.999). The
ptimal cutoff was 0.0164 g/l with a corresponding sensi-
ivity and specificity of 98.7% (95% CI: 97.8% to 99.4%)
nd 96.3% (95% CI: 94.4% to 97.7%), respectively. The
ositive likelihood ratio was 26.8 (95% CI: 26.3 to 27.2),
nd the negative likelihood ratio was 0.013 (95% CI: 0.006
o 0.03).
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Figure 5 ROC Curve Analysis of cTnI Levels
in Healthy Subjects and Patients With ACS
Receiver-operator characteristics (ROC) curve analysis of the discrimination of
healthy subjects and subjects with the acute coronary syndrome (GUSTO IV).
The ROC curve and 95% confidence interval are shown, as well as the sensitivity
and specificity at the optimal discrimination level 0.0064 g/l. Abbreviations as in
Figures 1 and 4.
he Diagnostic Discrimination Between Seemingly Healthy SubjectAcute Coronary Syndrome (GUSTO IV) at Different Cutoff LevelTable 1 The Diagnostic Discrimination Between Seemingly H athe Acute Coronary Syndrome (GUSTO IV) at Different
Cutoff Level, g/l Sensitivity, % (95% CI)
0.0032 (median) 98.3 (97.5–99.0)
0.0064 (ROC curve) 84.8 (82.8–86.6)
0.009 (97.5th percentile, age 60 yrs) 78.9 (76.7–81.0)
0.010 (99th percentile, age 60 yrs) 77.5 (75.3–79.7)
0.012 (97.5th percentile, age 60 yrs) 75.3 (73.0–77.5)
0.019 (99th percentile, age 60 yrs) 70.5 (68.1–72.9)LR  negative likelihood ratio; LR  positive likelihood ratio; CI  confidence interval; cTnI  c
OC  receiver-operator characteristic.Patient outcomes regarding death in 1 year or the
omposite end point of death and/or MI within 30 days is
hown in Table 2. In total, 110 deaths in 1 year and 106
eaths and/or MI were observed in the cohort. No events were
een below the median levels for healthy subjects and 4 and 6
vents, respectively, below the optimal cutoff of 0.0064 g/l
p  0.001 and p  0.01, respectively). At higher cutoffs, the
umber of events below the respective cutoff increased gradu-
lly, but were still significantly lower even at the highest cutoff
f 0.019 g/l (p  0.004 and p  0.007).
iscussion
he prototype cTnI assay used in this report was shown to
ave a sensitivity sufficient to measure cTnI levels in almost
ll healthy subjects. Thus, for the first time we have been
ble to define normal levels and have shown that they
ssentially follow a Gaussian distribution. By this assay we
Patients Withhe H gh-Sensitivity cTnI Access AssaySubjects a d Patients With
ff Levels of the High-Sensitivity cTnI Access Assay
Specificity, % (95% CI) LR LR
50.2 (45.8–54.5) 1.97 0.034
89.7 (86.8–92.2) 8.26 0.17
93.9 (91.5–95.8) 13.0 0.22
95.2 (93.1–96.9) 16.3 0.24
97.5 (95.8–98.7) 30.5 0.25
99.1 (97.8–99.7) 74.2 0.30
10
1
0.1
0.01
0.001
0.0001
Healthy Controls GUSTO IV-patients
cTnT <0.03 µg/L
cT
nI
, µµ µµ
g/
L
GUSTO IV-patients
cTnT ≥0.03 µg/L
P<0.0001
Figure 6 cTnI Levels in Healthy Subjects and in Patients
With ACS With cTnT Below or Above 0.03 g/l
The comparison of cTnI levels in seemingly healthy subjects and in patients
with the acute coronary syndrome (GUSTO IV) with cardiac troponin T (cTnT)
below or above 0.03 g/l. Results above 10 g/l were assigned 10 g/l. The
difference in cTnI levels between the cohorts was highly significant (p 
0.0001) (analysis of variance) as were the differences between healthy sub-
jects and either of the 2 GUSTO IV subsets (p  0.0001). Abbreviations as in
Figures 1 and 4.s andof tlthy
Cutoardiac troponin I; GUSTO IV  Global Utilization of Strategies To open Occluded arteries IV;
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High-Sensitivity cTnI Access Prototype Assay September 22, 2009:1165–72lso have shown that men and women have equal levels and
hat the levels were independent of age. The only apparent
ge and sex differences were related to the fact that outliers
ere overrepresented in the elderly cohort and in particular
mong men. This may be a reflection of subclinical disease
n some subjects with chronic myocardial injury and is not
nexpected considering the fairly advanced age of the
eference population. Slight cTnI elevations were previously
ound in a cohort of seemingly healthy 70-year-old men and
ere shown to be related to premature death in cardiovas-
ular disease (3). We also found that subjects with docu-
ented signs and symptoms of myocardial ischemia, also
hen not fulfilling the current definition of AMI (i.e.,
TnT 0.03 g/l), had on average significantly higher
evels than seemingly healthy subjects and that the event
ates regarding death and MI were related to the cTnI levels
ven at very low levels.
We defined the functional sensitivity of the cTnI by
eans of the imprecision profile derived from the CVs of
uplicate measurements of consecutive samples of patients
utcomes in Patients With the Acute Coronary SyndromeGUSTO IV) at Different Cutoff Levels of the High-Sensitivity cTnI ATable 2 Outcom s in Pati nts With t Acute Coronary Sy dro(GUSTO IV) at Different Cutoff Levels of the High-Sens
Death or Myocardial Infarct
Cutoff Level, g/l Below Equal to or Abo
0.0033 (median and 10% CV) 0% (0) 7.9% (110)
0.006 (ROC) 2.0% (4) 8.6% (106)
0.009 (97.5th percentile, age 60 yrs) 2.7% (8) 9.1% (102)
0.010 (99th percentile, age 60 yrs) 3.1% (10) 9.1% (100)
0.012 (97.5th percentile, age 60 yrs) 3.4% (12) 9.1% (98)
0.019 (99th percentile, age 60 yrs) 4.5% (19) 9.1% (91)
Figure 7 ROC Curve Analysis of cTnI Levels in Healthy Subject
ROC curve analysis of the discrimination of healthy subjects and subjects with the
0.03 g/l. The ROC curve and 95% confidence interval are shown, as well as the
0.0164 g/l, respectively. Abbreviations as in Figures 1, 4, and 6.Chi-square analysis.
CV  coefficient of variation; other abbreviations as in Table 1.ith suspicion of cardiac disease obtained from our emer-
ency department. The 10% and 20% CVs obtained from
hese results are extrapolated estimates because these CVs
ere not exceeded at any cTnI concentration. However, the
easonably correct estimates of the levels obtained were
upported by the distribution profile of the levels of the
eference samples because these also showed a harmonious
aussian distribution at the lower end of the concentra-
ions. Our results also highlight the difficulties in the
stablishment of clinically useful cutoffs. When we included
ll results from our reference samples, the 99th and 97.5th
ercentiles were 0.064 and 0.029 g/l, respectively. A look
t the distribution graph, however, clearly indicated that
hese levels were governed by results not belonging to the
istribution of the majority of results, which belonged to the
aussian distribution. Therefore, we applied an outlier
lgorithm (19), which eliminated all results exceeding 3
he upper quartile level. After such correction, the 99th and
7.5th percentiles were 0.022 and 0.012 g/l, respectively,
nd it was quite apparent that the distribution of the results
s Assay
cTnI Access Assay
30 Days Death at 1 Year
p Value* Below Equal to or Above p Value*
0.12 0% (0) 7.6% (106) 0.14
0.001 3.0% (6) 8.1% (100) 0.01
0.001 2.7% (8) 8.7% (98) 0.001
0.001 2.8% (9) 8.8% (97) 0.001
0.001 2.6% (9) 9.0% (97) 0.001
0.004 4.5% (19) 8.7% (87) 0.007
Patients With ACS With cTnT Below or Above 0.03 g/l
coronary syndrome (GUSTO IV) with cTnT levels below (left) or above (right)
ivities and specificities at the optimal discrimination levels of 0.0046 andccesme
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September 22, 2009:1165–72 High-Sensitivity cTnI Access Prototype Assayf the younger cohort, those 60 years of age, adapted to a
armonious Gaussian distribution, whereas the results of
he older cohort still had a tail upward not included in the
aussian distribution. In previous studies we showed that
he application of the 99th percentile for the cohort of
ounger subjects actually identified more subjects at risk of
remature death and/or MI (3,7). A similar approach in this
tudy would mean a 99th percentile URL of 0.010 g/l, and
s shown this was actually the case. The intriguing finding
n this study, however, is that we found significant differ-
nces in event rates even at lower levels.
One of the most spectacular findings in this study was the
arge difference between the results of the healthy cohort
nd the results of the GUSTO IV cohort. These results
ndicate that the vast majority of subjects included in the
USTO IV study had leakage of cTnI reflecting injury to
he myocardium likely as a consequence of acute ischemia in
ost cases. One important question, therefore, is whether
ormal levels of cTnI, as measured by the hypersensitive
ccess cTnI assay, can be used to exclude, rule out,
yocardial ischemia. The ROC curve analysis showed the
ptimal discrimination of health and disease at the level of
.0064 g/l. At this level, the negative predictive value was
8.5%, but to achieve negative predictive values of more
han 90% the cTnI levels should be below the median levels
f the healthy subjects, that is, 0.0032 g/l. Indeed, below
his level we had no adverse outcomes regarding death
ithin 1 year or death/MI within 30 days among the
USTO IV subjects. The above calculations were made on
he assumption of accurate inclusions of all subjects among
he healthy and diseased cohorts, which may not be the case.
n a previous randomized clinical trial including patients
ith a clinical diagnosis of unstable angina, 14% of the
atients included in the trial had no significant luminal
iameter stenosis of a major coronary artery (20), and in
nother ACS trial (21), 32% of those without detectable
roponin T had no significant coronary stenosis. Hence, it is
ikely that a small proportion of patients included in the
USTO IV trial had other causes of their chest pain at
nclusion than true myocardial ischemia. Indeed, when we
sed cTnT levels as surrogate markers of non–ST-segment
levation MI and unstable angina, the distinction between
I and healthy subjects was very accurate, whereas the
istinction between unstable angina and healthy subjects
as less accurate, with sensitivities and specificities in the
ange of 75% to 80%. Therefore, further studies in carefully
haracterized patient materials are needed to establish the
rue sensitivity and specificity and to accurately define
ecision limits. However, the present results suggest that it
ight be possible to define such rule-out limits, and this
ould obviously have a very important impact on the clinical
anagement of patients with suspected ACS. Slightly
levated levels of cTnI, however, are found, aside from ACS
n many other disorders affecting the heart directly or
ndirectly (22,23). Therefore, in the future management of
ur patients with the aid of these hypersensitive cardiac
Uroponin assays, we may need to define new decision limits
nd criteria for the diagnosis of acute ischemic diseases of
he myocardium and for prediction of future events. The
urrent consensus criteria suggest a rise and fall above the
9th percentile URL in cardiac troponins in addition to
ther symptoms and signs of ischemia as the diagnostic
riteria for AMI (1). With the hypersensitive cardiac tro-
onin assays and with the lowering of the 99th percentile
urther, it is predicted that such changes will be seen much
ore frequently in patients without classical AMI caused by
laque rupture with a superimposed thrombus in the coro-
ary arteries, and that this will prompt the clinician to be
ore active in defining the specific cause of the elevation in
ach case. Therefore, can we define criteria and decision
imits that will guide the clinician to take appropriate action
ithout jeopardizing the safety of our patients? When it
omes to prediction, the situation seems slightly less com-
licated because this and other studies have shown that even
inor elevations of cardiac troponins are associated with
nfavorable long-term outcome and an increased risk of
remature death and/or MI (3,7,8). Thus, any elevations
bove the low 99th percentile are important signs, and the
ituation seems almost dichotomous. Highly sensitive tro-
onin assays, therefore, might also be useful in the screening
ituation of populations at risk. With the current knowledge
e may now adopt conventional criteria for the definition of
hat are normal or abnormal levels of cTnI, that is, use the
7.5th percentiles instead of the 99th percentiles because of
he inherent difficulties of accurate definition of the latter.
n addition to this, we may define levels below or above
hese levels to meet specific clinical needs, but as indicated
reviously, this will have to await further studies.
onclusions
he hypersensitive cTnI assay from Beckman Coulter
llows us to define normal plasma levels of cTnI. This
nformation is novel and very important for our understand-
ng of how to optimize the clinical utility of cTnI measure-
ents in the diagnosis and outcome prediction of patients
ith cardiovascular disease. Our data also suggest that the
ypersensitive cTnI assay may be a means to rule out
atients with suspected ischemia of the myocardium and an
nfavorable outcome.
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